| Literature DB >> 23442200 |
Angie Mae Rodday1, Norma Terrin, Susan K Parsons.
Abstract
BACKGROUND: Pediatric health-related quality of life (HRQL) measures explore multiple domains of HRQL. To ease administration, burden, and implementation, we created a 7-item unidimensional global HRQL scale for children. This paper evaluates the psychometric properties of the global HRQL scale in children undergoing hematopoietic stem cell transplant (HSCT) and describes the trajectory of global HRQL scores over the 12-month course following HSCT.Entities:
Mesh:
Year: 2013 PMID: 23442200 PMCID: PMC3644228 DOI: 10.1186/1477-7525-11-26
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Global HRQL items for parent proxy report
| During the past week, how would you rate the general quality of your child’s life in each of the following areas? | Excellent Very good Good |
| a. Physical health | Fair |
| b. Mental health | Poor |
| c. Family life | |
| d. Friendship | |
| e. Self-confidence | |
| f. Fun | |
| g. Life enjoyment |
a Wording for the adolescent self-report items replaces the phrase “your child’s” with “your”.
Baseline demographic and clinical characteristics for parent proxy report and adolescent self-report
| Parent proxy report, | |
| Parent age, mean ( | 39.8 (7.1) |
| Parent female, | 261 (83.7%) |
| Baseline parental emotional functioning, mean ( | 49.9 (19.2) |
| Child age, mean ( | 10.9 (4.2) |
| Child female, | 158 (50.6%) |
| Transplant Type | |
| Autologous | 70 (22.4%) |
| Allogeneic, related | 84 (26.9%) |
| Allogeneic, unrelated | 158 (50.6%) |
| Causal Malignancy, | 236 (75.6%) |
| Duration of illness, median (25th to 75th) | 11.0 (5.0, 40.0) |
| Study, | |
| JTR | 164 (52.9%) |
| HSCT-CHESS™ | 147 (47.1%) |
| Baseline measures during preparative regimen, | 96 (30.8%) |
| Adolescent self-report, | |
| Child age, mean ( | 15.6 (1.8) |
| Child female, | 54 (46.2%) |
| Transplant Type, | |
| Autologous | 28 (23.9%) |
| Allogeneic, related | 31 (26.5%) |
| Allogeneic, unrelated | 58 (49.6%) |
| Causal Malignancy, | 96 (82.1%) |
| Duration of illness, median (25th to 75th) | 12.0 (5.0, 34.0) |
| Study, | |
| JTR | 59 (50.4%) |
| HSCT-CHESS™ | 58 (49.6%) |
| Baseline measures during preparative regimen, | 39 (33.3%) |
Abbreviations: SD standard deviation, JTR Journeys to Recovery, HSCT-CHESS™ Hematopoietic Stem Cell Transplant-Comprehensive Health Enhancement Support Study (CHESS™).
Baseline item and scale psychometrics
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||||
| Global Scale | 61.2 (21.9) | 0.0 | 4.5 | 0.3 | 58.9 (22.0) | 0.0 | 3.4 | 0.0 | 69.0 (18.2) | 0.0 | 2.6 | 0.9 |
| Items | | | | | | | | | | | | |
| Physical health | 54.0 (26.7) | 5.2 | 11.3 | 0.6 | 50.6 (26.3) | 5.2 | 9.5 | 0.9 | 58.2 (27.1) | 6.0 | 15.5 | 0.9 |
| Mental health | 60.6 (28.4) | 2.9 | 20.9 | 0.3 | 57.5 (28.9) | 4.3 | 18.0 | 0.0 | 69.6 (25.7) | 1.7 | 29.3 | 0.9 |
| Family life | 65.8 (27.2) | 1.9 | 25.4 | 0.3 | 64.7 (26.3) | 1.7 | 23.1 | 0.0 | 75.0 (24.3) | 0.0 | 38.3 | 1.7 |
| Friendships | 60.0 (30.5) | 8.4 | 21.9 | 0.6 | 60.5 (30.5) | 8.6 | 23.1 | 0.0 | 73.9 (29.1) | 4.4 | 44.4 | 1.7 |
| Self-confidence | 67.4 (25.1) | 1.3 | 23.5 | 0.3 | 66.2 (25.5) | 1.7 | 21.4 | 0.0 | 72.0 (24.3) | 1.7 | 31.0 | 0.9 |
| Fun | 60.0 (28.8) | 7.1 | 19.0 | 0.3 | 57.3 (27.9) | 6.0 | 15.4 | 0.0 | 68.5 (29.4) | 6.1 | 33.9 | 1.7 |
| Life Enjoyment | 60.4 (28.2) | 3.9 | 19.6 | 0.3 | 55.6 (26.9) | 5.1 | 11.1 | 0.0 | 66.4 (27.6) | 6.0 | 25.0 | 0.9 |
Abbreviations: SD standard deviation.
Multivariable pattern mixture models
| | ||||
|---|---|---|---|---|
| Intercept | 49.7 (4.1) | <.0001 | 90.3 (13.5) | <.0001 |
| Time | | | | |
| Baseline (reference) | | | | |
| 45 days | -8.5 (2.4) | .0003 | -3.2 (3.4) | 0.35 |
| 3 months | -8.0 (2.6) | .002 | -6.0 (3.7) | 0.11 |
| 6 months | -4.8 (2.6) | .07 | -3.5 (4.1) | 0.39 |
| 12 months | 2.0 (4.8) | .68 | -0.1 (5.1) | 0.98 |
| Baseline timing | -11.8 (2.7) | <.0001 | -14.3 (3.4) | <.0001 |
| Time*Baseline timing | | | | |
| Baseline*baseline timing (reference) | | | | |
| 45 days*baseline timing | 7.5 (3.4) | .03 | 8.6 (4.7) | 0.06 |
| 3 months*baseline timing | 6.8 (3.7) | .07 | 9.7 (4.9) | 0.048 |
| 6 months*baseline timing | 11.5 (3.7) | .002 | 11.7 (5.3) | 0.03 |
| 12 months*baseline timing | 9.6 (5.8) | .10 | 8.8 (6.3) | 0.16 |
| Baseline parental emotional functioning for ½ | 3.8 (0.4) | <.0001 | 2.2 (0.7) | 0.002 |
| Baseline parental emotional functioning*parent rater for ½ | | | 1.7 (0.6) | 0.003 |
| Child age | -0.5 (0.2) | .008 | -1.7 (0.8) | 0.03 |
| Log duration of illness | -1.2 (0.7) | .07 | | |
| Transplant Type | | | | |
| Autologous | 4.2 (2.2) | .06 | | |
| Allogeneic, related | 4.7 (2.0) | .02 | | |
| Allogeneic, unrelated (reference) | | | | |
| Early complicationsb | -1.8 (2.7) | .49 | -2.0 (3.4) | 0.57 |
| Time*early complicationsb | | | | |
| Baseline*early complications (reference) | | | | |
| 45 days*early complications | -6.4 (3.4) | .06 | -10.1 (4.7) | 0.03 |
| 3 months*early complications | 2.3 (3.6) | .52 | -2.2 (4.9) | 0.66 |
| 6 months*early complications | 4.1 (3.8) | .27 | -3.3 (5.4) | 0.54 |
| 12 months*early complications | 0.3 (6.2) | .96 | -1.2 (6.3) | 0.85 |
| Late cGVHDc | 7.6 (7.7) | .32 | | |
| Time*Late cGVHDc | | | | |
| Baseline*late cGVHD (reference) | | | | |
| 45 days* late cGVHD | -12.5 (9.3) | .18 | | |
| 3 months* late cGVHD | -21.9 (9.7) | .02 | | |
| 6 months* late cGVHD | -20.0 (9.4) | .03 | | |
| 12 months* late cGVHD | -14.3 (10.5) | .17 | | |
| Parent Female | | | -1.5 (4.0) | 0.71 |
| Parent Rater | | | -13.3 (4.6) | 0.004 |
| Parent female*Parent rater | | | -6.6 (3.2) | 0.04 |
| Time*Parent rater | | | | |
| Baseline*parent rater (reference) | | | | |
| 45 days*parent rater | | | -4.5 (2.4) | 0.054 |
| 3 months*parent rater | | | -3.3 (2.4) | 0.18 |
| 6 months*parent rater | | | -1.5 (2.7) | 0.57 |
| 12 months*parent rater | 1.1 (2.9) | 0.71 | ||
Abbreviations: SE standard error, SD standard deviation, cGVHD chronic graft versus host disease.
a A half standard deviation for the parent emotional functioning is equal to 9.5.
b Early complications refers to at least one of the following within the first 3 months: aGVHD of grade 2 or higher, intermediate or poor toxicity, or localized or systemic infection.
c Late cGVHD refers to limited or extensive cGVHD between 6 and 12 months.
Figure 1Global HRQL means scores for “All Children” and “Adolescent Only” based on pattern mixture models. Abbreviations: HRQL = health-related quality of life; HSCT = hematopoietic stem cell transplant; Adol = adolescent. Notes: Early complications refers to at least one of the following within the first 3 months: aGVHD of grade 2 or higher, intermediate or poor toxicity, or localized or systemic infection. Late cGVHD refers to limited or extensive cGVHD between 6 and 12 months.